December 18th- ASH 2025 Highlight: Stem Cell Boost for CAR-T–Related Hematologic Toxicity in multiple myeloma: Real-World Evidence CME Congresses . December 18th- ASH 2025 Highlight: Stem Cell Boost for CAR-T–Related Hematologic Toxicity in multiple myeloma: Real-World Evidence December 16th- ASH 2025 Highlight- Menin Inhibitors AML Update CME Congresses . December 16th- ASH 2025 Highlight- Menin Inhibitors AML Update December 12th- ASH 2025 Spotlight: BRUIN CLL-313 Pirtobrutinib Moves to the Frontline CME Congresses . December 12th- ASH 2025 Spotlight: BRUIN CLL-313 Pirtobrutinib Moves to the Frontline December 10th- ASH 2025 Spotlight: Sustained MRD as a Transformative Endpoint in Transplant-Ineligible Myeloma- Insights from the BENEFIT Phase 3 Study CME Congresses . December 10th- ASH 2025 Spotlight: Sustained MRD as a Transformative Endpoint in Transplant-Ineligible Myeloma- Insights from the BENEFIT Phase 3 Study December 9th- ASH 2025 Spotlight: inMMyCAR: First-in-Human In Vivo CAR-T for Relapsed/Refractory Myeloma CME Congresses . December 9th- ASH 2025 Spotlight: inMMyCAR: First-in-Human In Vivo CAR-T for Relapsed/Refractory Myeloma December 9th- ASH 2025 Spotlight: MajesTEC-3: A Landmark Phase 3 Trial in Relapsed/Refractory Myeloma CME Congresses . December 9th- ASH 2025 Spotlight: MajesTEC-3: A Landmark Phase 3 Trial in Relapsed/Refractory Myeloma December 9th- ASH 2025 Spotlight: Real-World Symptom Improvement With Belumosudil in Chronic GVHD CME Congresses . December 9th- ASH 2025 Spotlight: Real-World Symptom Improvement With Belumosudil in Chronic GVHD December 9th- ASH 2025 Spotlight: Response Dynamics to Belumosudil in Chronic GVHD CME Congresses . December 9th- ASH 2025 Spotlight: Response Dynamics to Belumosudil in Chronic GVHD December 8th- ASH 2025 Highlight: MaaT013 in Steroid- and Ruxolitinib-Refractory Acute GI GVHD CME Congresses . December 8th- ASH 2025 Highlight: MaaT013 in Steroid- and Ruxolitinib-Refractory Acute GI GVHD December 8th- ASH 2025 Highlight: What’s New in Myeloid Malignancies at ASH 2025? CME Congresses . December 8th- ASH 2025 Highlight: What’s New in Myeloid Malignancies at ASH 2025? Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Page21 Page22 Page23 Page24
